top of page

EndPoints Webinar 2022: Why Oncology Needs More Than MRD

Personalis
11/16/22, 3:00 PM
America/Chicago UTC -5

Description

Stephane Mouradian, PhD
Senior Vice President, Business Development and Marketing
Personalis, Inc.

 

November 16, 2022 | 12:00 PM – 1:00 PM EST

 

Why Oncology Needs More Than MRD

 

In parallel with the evolution of cancer therapies over time, the field of molecular diagnostics continues to mature, bringing innovative solutions to precision medicine. The value of using molecular residual disease (MRD) to monitor a patient’s journey post-diagnosis has demonstrated value in oncology, but is this tool sufficient for clinicians to make informed treatment decisions throughout the patient’s journey? By combining multiple analyses in a platform-based approach, Personalis is developing a holistic solution to managing a patient’s care including therapy selection, treatment and recurrence monitoring, all from a single specimen collected at clinical diagnosis.

 

In this webinar, Stephane will present:

  • Example clinical use cases of a tumor-normal ctDNA assay
  • Technical validation data on a variety of cancer specimens
  • A future vision for comprehensive diagnostics in precision medicine
Previous registration necessary?

NO

YES
Simultaneous translation ?

NO

YES
Will it be recorded?
NO
YES

Why Oncology Needs More Than MRD

Inglês

Description

Speakers

Stephane Mouradian

Speakers

Link to the Event

Banner to the Event

EndPoints Webinar 2022: Why Oncology Needs More Than MRD
Link to Event
Banner
Registro
bottom of page